Obstetric and thrombotic outcomes among pregnant patients with myeloproliferative neoplasms: a propensity score matched real-world analysis
Annals of Hematology · 22.09.2026 · 105 (11)
DOI: 10.1007/s00277-026-07285-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 22.09.2026. Verfasst von Nikhil Vojjala und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Thrombosis, Pregnancy Complications, Neoplastic, Pregnancy Complications, Hematologic. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pregnancies complicated by BCR::ABL1-negative myeloproliferative neoplasms (MPNs) are associated with increased maternal and thrombotic risk; however, large real-world comparative data remain limited. We performed a multicenter retrospective propensity score-matched cohort study using the TriNetX database to evaluate maternal, obstetric, and thrombotic outcomes among pregnant patients with MPN compared with matched non-MPN controls. Baseline demographics, comorbidities, and antithrombotic medication use were balanced after matching (standardized mean difference < 0.1). Among 4,467,127 pregnancies, 4,563 patients had MPN, most commonly essential thrombocytosis (85%). Compared with matched controls, MPN pregnancies had significantly higher all-cause mortality (1.1% vs. 0.2%; hazard ratio [HR] 5.4, 95% CI 2.7-10.8), gestational hypertension (11.1% vs. 7.8%; HR 1.3, 95% CI 1.1-1.5), preeclampsia/eclampsia (10.4% vs. 5.3%; HR 1.8, 95% CI 1.6-2.1), preterm labor (6.1% vs. 3.7%; HR 1.5, 95% CI 1.2-1.8), intrauterine growth restriction (7.3% vs. 5.1%; HR 1.3, 95% CI 1.1-1.7), postpartum hemorrhage (5.5% vs. 3.8%; HR 1.3, 95% CI 1.1-1.6), and venous thromboembolism (2.7% vs. 0.7%; HR 3.2, 95% CI 2.2-4.6). Arterial thrombotic events were not significantly different between groups. Pregnancies in patients with MPN are associated with significantly increased maternal, obstetric, and venous thrombotic complications, highlighting the need for multidisciplinary management and individualized thromboprophylaxis strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
- Department of Internal Medicine, University of Pittsburgh Medical Center, Harrisburg, PA, USA.
- Division of Hematology and Oncology, Karmanos Cancer Institute, Detroit, MI, USA.
- Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI, USA.
- Department of Internal Medicine, Northwestern Memorial Hospital, Chicago, IL, USA.
- Division of Hematology and Oncology, Karmanos Cancer Institute, Detroit, MI, USA. singhv@karmanos.org.
Zitieren
APA
Vojjala, N., Srungavarapu, S. R., Nanjareddy, S., Kannan, M. V., Prabhu, R., Arsene, C., Krishnamoorthy, G., & Singh, V. (2026). Obstetric and thrombotic outcomes among pregnant patients with myeloproliferative neoplasms: a propensity score matched real-world analysis. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07285-6
Vancouver
Vojjala N, Srungavarapu SR, Nanjareddy S, Kannan MV, Prabhu R, Arsene C, et al. Obstetric and thrombotic outcomes among pregnant patients with myeloproliferative neoplasms: a propensity score matched real-world analysis. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07285-6
BibTeX
@article{Vojjala2026,
author = {Vojjala, Nikhil and Srungavarapu, Sambasiva Rao and Nanjareddy, Sushmitha and Kannan, Mani Vignesh and Prabhu, Rishab and Arsene, Camelia and Krishnamoorthy, Geetha and Singh, Vijendra},
title = {Obstetric and thrombotic outcomes among pregnant patients with myeloproliferative neoplasms: a propensity score matched real-world analysis},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07285-6}
}
EUVIMED